CN112514902A - Bactericide containing quinazolinone and kasugamycin and application of bactericide in preventing and treating plant diseases - Google Patents
Bactericide containing quinazolinone and kasugamycin and application of bactericide in preventing and treating plant diseases Download PDFInfo
- Publication number
- CN112514902A CN112514902A CN202011453914.5A CN202011453914A CN112514902A CN 112514902 A CN112514902 A CN 112514902A CN 202011453914 A CN202011453914 A CN 202011453914A CN 112514902 A CN112514902 A CN 112514902A
- Authority
- CN
- China
- Prior art keywords
- kasugamycin
- quinazolinone
- bactericide
- plant diseases
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical compound C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title claims abstract description 65
- PVTHJAPFENJVNC-MHRBZPPQSA-N kasugamycin Chemical compound N[C@H]1C[C@H](NC(=N)C(O)=O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O PVTHJAPFENJVNC-MHRBZPPQSA-N 0.000 title claims abstract description 65
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 27
- 239000003899 bactericide agent Substances 0.000 title claims abstract description 27
- 201000010099 disease Diseases 0.000 title claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 239000000375 suspending agent Substances 0.000 claims abstract description 25
- 241000196324 Embryophyta Species 0.000 claims abstract description 11
- 244000061458 Solanum melongena Species 0.000 claims abstract description 11
- 235000002597 Solanum melongena Nutrition 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 241000207199 Citrus Species 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 235000020971 citrus fruits Nutrition 0.000 claims abstract description 9
- 239000000839 emulsion Substances 0.000 claims abstract description 8
- 239000004562 water dispersible granule Substances 0.000 claims abstract description 8
- 230000001580 bacterial effect Effects 0.000 claims abstract description 4
- 240000008067 Cucumis sativus Species 0.000 claims abstract description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 238000009924 canning Methods 0.000 claims abstract description 3
- 238000005507 spraying Methods 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 2
- 240000003768 Solanum lycopersicum Species 0.000 claims description 2
- 230000002070 germicidal effect Effects 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003139 biocide Substances 0.000 claims 1
- 230000000855 fungicidal effect Effects 0.000 claims 1
- 239000000417 fungicide Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 239000000203 mixture Substances 0.000 abstract description 12
- 238000010790 dilution Methods 0.000 abstract description 7
- 239000012895 dilution Substances 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000001228 spectrum Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 32
- 238000000034 method Methods 0.000 description 20
- 239000003814 drug Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241000123650 Botrytis cinerea Species 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 10
- 229940051841 polyoxyethylene ether Drugs 0.000 description 10
- 229920000056 polyoxyethylene ether Polymers 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000575 pesticide Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 150000002191 fatty alcohols Chemical class 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 6
- 235000010234 sodium benzoate Nutrition 0.000 description 6
- 239000004299 sodium benzoate Substances 0.000 description 6
- DMAXMXPDVWTIRV-UHFFFAOYSA-N 2-(2-phenylethyl)phenol Chemical compound OC1=CC=CC=C1CCC1=CC=CC=C1 DMAXMXPDVWTIRV-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- -1 polyoxyethylene phosphate Polymers 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000187214 Streptomyces kasugaensis Species 0.000 description 2
- 238000012271 agricultural production Methods 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- KCSKLFOUSOPWDI-UHFFFAOYSA-N 2-(propylamino)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(NCCC)=NC(=O)C2=C1 KCSKLFOUSOPWDI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000005656 Fenazaquin Substances 0.000 description 1
- 239000005785 Fluquinconazole Substances 0.000 description 1
- 241000228456 Leptosphaeria Species 0.000 description 1
- 231100000674 Phytotoxicity Toxicity 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000589655 Xanthomonas citri Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- DMYHGDXADUDKCQ-UHFFFAOYSA-N fenazaquin Chemical compound C1=CC(C(C)(C)C)=CC=C1CCOC1=NC=NC2=CC=CC=C12 DMYHGDXADUDKCQ-UHFFFAOYSA-N 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005553 polystyrene-acrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
- A01N43/14—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings
- A01N43/16—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom six-membered rings with oxygen as the ring hetero atom
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention discloses a bactericide containing quinazolinone and kasugamycin and application thereof in preventing and treating plant diseases. The active ingredients of the mixed bactericide comprise quinazolinone and kasugamycin, and the mass ratio of the quinazolinone to the kasugamycin is (1-30): 30 to 1. The mixed bactericide can be prepared into suspending agents, soluble liquid agents, aqueous emulsion or water dispersible granules and other dosage forms. The mixed bactericide can prevent and treat plant diseases, can prevent and treat the plant diseases such as citrus canker, cucumber bacterial angular leaf spot, eggplant wilt, eggplant gray mold and the like by spraying or canning the mixed bactericide, and the dilution multiple is preferably less than 1000 times. The synergistic effect of the mixed bactericide is obvious, and the control effect is improved; the action mechanisms of the two bactericides are different, so that the prevention and treatment spectrum of the composition is expanded; but also the resistance generation can be slowed down.
Description
Technical Field
The invention relates to a bactericide containing quinazolinone and kasugamycin and application thereof in preventing and treating plant diseases, belonging to the technical field of pesticides.
Background
The pesticide is an important agricultural production data, and the use of the pesticide is one of important means for ensuring high yield, high quality and high efficiency of agricultural production. At present, in agricultural pest control, the use of chemical pesticides accounts for more than 80%, but serious 3R (namely resistance, rampant and residue) problems are caused along with long-term use of the chemical pesticides. Therefore, the development of highly effective, environmentally friendly and low toxic chemical or biological pesticides is one of the important tasks in current research and development.
Quinazolinone belongs to quinoline alkaloids containing pyrimidine heterocycle, has stronger biological activity in the fields of medicine and pesticide, and mainly shows better effects of sterilization, disinsection and antivirus in the field of pesticide. The bactericide fluquinconazole and the acaricide fenazaquin with better effect on the market are developed from quinazolinone compounds. Kasugamycin is a metabolite produced by Streptomyces kasugaensis (Streptomyces kasugaensis), has strong systemic permeability and has prevention and treatment effects, and the action mechanism of the kasugamycin is to interfere the amino acid metabolism of a pathogenic bacterium esterase system, destroy the synthesis of protein, inhibit the growth of hypha and cause cell granulation, so that the pathogenic bacterium loses the reproductive and infection capacity, and the aims of killing the pathogenic bacterium and preventing and treating diseases are fulfilled. Therefore, it is necessary to compound quinazolinone and kasugamycin and study the control effect of the compound medicament.
Disclosure of Invention
The invention aims to provide a bactericidal agent containing quinazolinone and kasugamycin.
The active ingredients of the mixed bactericide provided by the invention consist of quinazolinone and kasugamycin;
the mass ratio of the quinazolinone to the kasugamycin is 1-30: 30-1;
preferably, the mass ratio of the quinazolinone to the kasugamycin is 1-12: 12-1 or 12-1: 1 or 12: 1.
the mixed bactericide can be prepared into suspending agents, soluble liquid agents, aqueous emulsion or water dispersible granules and other dosage forms.
In the mixed bactericide, the sum of the mass percentages of the quinazolinone and the kasugamycin can be 1-80%, preferably 1-60% or 1-26% or 26%, and the toxicity and the residue of the mixed bactericide reach better balance and the cost is lower.
The mixed bactericide can prevent and treat plant diseases, can prevent and treat the plant diseases such as citrus canker, cucumber bacterial angular leaf spot, eggplant wilt, eggplant gray mold, tomato gray mold and the like by spraying or canning the mixed bactericide, and the dilution multiple is preferably less than 1000 times.
The synergistic effect of the mixed bactericide is obvious, and the control effect is improved; the action mechanisms of the two bactericides are different, so that the prevention and treatment spectrum of the composition is expanded; but also the resistance generation can be slowed down.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1 preparation of a suspension containing quinazolinone and kasugamycin
The weight percentage of each component is as follows: 2% of kasugamycin, 24% of quinazolinone, 3% of alkylphenol polyoxyethylene phosphate, 2% of polystyrene acrylate carboxylate copolymer, 1% of fatty alcohol polyoxyethylene ether, 0.2% of xanthan gum, 1% of magnesium aluminum silicate, 0.2% of sodium benzoate, 0.5% of polydimethylsiloxane emulsion and the balance of water which is used for supplementing to 100%.
The method comprises the following specific steps:
(1) adding water, an organic silicon defoaming agent, alkylphenol polyoxyethylene phosphate, a polystyrene acrylic carboxylate copolymer and fatty alcohol polyoxyethylene ether into a beaker, and uniformly dispersing;
(2) adding magnesium aluminum silicate, kasugamycin and quinazolinone into a beaker, and dispersing for 5min until the liquid medicine is homogeneous;
(3) transferring the liquid medicine to a sand mill for sand milling for 1.5 hours until the particle size is less than 5 mu m;
(4) adding xanthan gum and sodium benzoate into the liquid medicine, and uniformly stirring to obtain the suspension of the composition of kasugamycin and quinazolinone.
Example 2 preparation of a soluble solution containing quinazolinone and kasugamycin
The weight percentage of each component is as follows: 2% of kasugamycin, 24% of quinazolinone, 20% of xylene, 10% of phenethyl phenol polyoxyethylene ether, 5% of fatty alcohol polyoxyethylene ether, 0.2% of sodium benzoate and the balance of water for supplementing to 100%.
The method comprises the following specific steps:
(1) firstly, adding kasugamycin and quinazolinone into a beaker, then adding dimethylbenzene, starting stirring until the original drug is completely dissolved;
(2) adding the phenethyl phenol polyoxyethylene ether, the fatty alcohol polyoxyethylene ether and the sodium benzoate while stirring, continuously stirring until the phenethyl phenol polyoxyethylene ether, the fatty alcohol polyoxyethylene ether and the sodium benzoate are completely dissolved, and then adding water to obtain the soluble solution of the composition of the kasugamycin and the quinazolinone.
Example 3 preparation of an aqueous emulsion containing quinazolinone and kasugamycin
The weight percentage of each component is as follows: 2% of kasugamycin, 24% of quinazolinone, 3% of phenethyl phenol polyoxyethylene polyoxypropylene ether, 1% of fatty alcohol polyoxyethylene ether, 20% of xylene, 0.2% of sodium benzoate, 0.5% of an organic silicon defoamer and the balance of water to make up to 100%.
The method comprises the following specific steps:
(1) firstly, weighing kasugamycin and quinazolinone, adding the kasugamycin and the quinazolinone into a beaker, then adding dimethylbenzene, starting stirring, and stirring until the kasugamycin and the quinazolinone are completely dissolved to prepare an oil phase;
(2) adding phenethyl phenol polyoxyethylene polyoxypropylene ether, fatty alcohol polyoxyethylene ether, water, a preservative and a defoaming agent into a beaker, starting stirring, and stirring until the components are completely dissolved to prepare a water phase;
(3) adding the water phase into the oil phase, and stirring uniformly. And then shearing for 10min to obtain the composition aqueous emulsion of kasugamycin and quinazolinone.
Example 4 preparation of Water dispersible granules containing quinazolinone and kasugamycin
The weight percentage of each component is as follows: 2% of kasugamycin, 24% of quinazolinone, 2% of sodium dodecyl sulfate, 10% of alkyl naphthalene sulfonate, 5% of dispersing agent NNO and the balance of ammonium sulfate for supplementing to 100%.
The method comprises the following specific steps:
(1) uniformly mixing kasugamycin, quinazolinone, sodium lauryl sulfate, alkyl naphthalene sulfonate, a diffusant NNO and ammonium sulfate;
(2) crushing the uniformly mixed materials by airflow to 800 meshes;
(3) adding the crushed materials into a container, adding a small amount of water, and kneading;
(4) adding the kneaded material into an extrusion granulator, and carrying out extrusion granulation;
(5) putting the manufactured granules into a drying oven for drying;
(6) and sieving the dried particles, and screening out powder and the like which are not granulated to obtain the kasugamycin and quinazolinone composition water dispersible granules.
EXAMPLE 5 indoor bacteriostasis test of different formulations of quinazolinone and kasugamycin containing compositions against citrus canker
1. Reagent for testing
26% kasugamycin quinazolinone suspension, prepared according to example 1
26% kasugamycin quinazolinone solution, example 2 preparation
26% kasugamycin quinazolinone aqueous emulsion, example 3 preparation
26% kasugamycin quinazolinone water dispersible granule, example 4 preparation
2. Test method
A bacteriostatic test is carried out by adopting a filter paper method, 2mL of prepared bacterial suspension of citrus canker pathogen, namely citrus Xanthomonas citri subsp. Preparing the reagent to be tested into the required concentration, clamping a piece of sterile filter paper (diameter is 0.6cm) by using a sterile forceps, soaking the sterile filter paper into the liquid medicine, stopping the sterile filter paper for a moment at the edge of the container when the sterile filter paper is clamped out, filtering off the redundant liquid medicine, placing the filter paper in the center of a medicine-containing flat plate, slightly pressing the filter paper by using the forceps to ensure that the filter paper is fully and tightly attached to a culture medium, and measuring the diameter of a bacteriostatic ring after the culture dish is placed in a constant-temperature incubator at 28 ℃ for culturing for 48 hours. Each treatment was repeated 3 times, and a blank was made with a sterile filter paper sheet soaked in sterile water.
3. Test results
The test results are shown in table 1, when the content of kasugamycin in the composition is 2% and the content of quinazolinone in the composition is 24%, the difference of the antibacterial effect of the compositions of different dosage forms is large. When the test agent is diluted by 1000 times, the bacteriostatic effect of the soluble agent is optimal, and the effect of the soluble agent is not obviously different from that of an aqueous emulsion, but is obviously higher than that of a suspending agent and water dispersible granules. The diameter of the bacteriostatic circle of the suspending agent is 19.3mm, which is obviously higher than that of the water dispersible granules.
TABLE 126% kasugamycin-quinazolinone composition with different dosage forms has indoor bacteriostatic action on citrus canker pathogen
Note: letters after the same row of numbers indicate significant differences at P < 0.05 level (Duncan's New Bipolar Difference method).
EXAMPLE 6 indoor bacteriostasis test of suspensions containing quinazolinone and kasugamycin against Leptosphaeria citricola
1. Reagent for testing
2% kasugamycin solution from Qingdao Star brand crop science, Inc
24% quinazolinone suspension, prepared according to the method of example 1
26% kasugamycin quinazolinone suspension, prepared according to example 1
2. Test method
A bacteriostatic test is carried out by adopting a filter paper method, 2mL of the prepared suspension of the citrus canker pathogenic bacteria is added into a sterilized LB culture medium (45-60 ℃), the culture medium and the suspension are mixed uniformly by slight oscillation, and the culture dish is poured to prepare a bacteria-containing flat plate. Preparing the reagent to be tested into the required concentration, clamping a piece of sterile filter paper (diameter is 0.6cm) by using a sterile forceps, soaking the sterile filter paper into the liquid medicine, stopping the sterile filter paper for a moment at the edge of the container when the sterile filter paper is clamped out, filtering off the redundant liquid medicine, placing the filter paper in the center of a medicine-containing flat plate, slightly pressing the filter paper by using the forceps to ensure that the filter paper is fully and tightly attached to a culture medium, and measuring the diameter of a bacteriostatic ring after the culture dish is placed in a constant-temperature incubator at 28 ℃ for culturing for 48 hours. Each treatment was repeated 3 times, and a blank was made with a sterile filter paper sheet soaked in sterile water.
3. Test results
The test results are shown in table 2, when the test agent is diluted by 1000 × for treatment, the diameter of the bacteriostatic circle of the 24% kasugamycin-quinazolinone suspending agent is significantly larger than that of the bacteriostatic circle of the 2% kasugamycin aqueous solution and that of the 22% quinazolinone suspending agent, and the combination of the kasugamycin and the quinazolinone has a synergistic effect. When the 26% kasugamycin-quinazolinone suspending agent is diluted by 500 times, the diameter of the inhibition zone is 22.6mm, and has no significant difference with 1000 times of dilution, and when the 26% kasugamycin-quinazolinone suspending agent is diluted by 2000 times, the diameter of the inhibition zone has no significant difference with 22% quinazolinone suspending agent (1000 times).
Indoor bacteriostatic action of table 226% kasugamycin and quinazolinone suspending agent on citrus canker pathogen
Note: letters after the same row of numbers indicate significant differences at P < 0.05 level (Duncan's New Bipolar Difference method).
Example 7, 26% kasugamycin quinazolinone suspension indoor tests for inhibition of Botrytis cinerea
1. Reagent for testing
2% kasugamycin solution from Qingdao Star brand crop science, Inc
24% quinazolinone suspension, prepared according to the method of example 1
26% kasugamycin quinazolinone suspension, prepared according to example 1
2. Test method
Adopting a hypha growth rate method, preparing a reagent to be tested into a required concentration, uniformly mixing the reagent with a melted and cooled PDA culture medium (45-50 ℃), pouring a flat plate to prepare a medicine-containing flat plate, taking the PDA culture medium added with isometric sterile water as a control, and inoculating a Botrytis cinerea-Botrytis cinerea (Botrytis cinerea) cake with the diameter of 6mm in the center of the flat plate. When the control grows over 3/4 culture dishes, the cross method measures the colony diameters of the control group and the treatment group, calculates the bacteriostasis rate, and sets 3 times for each treatment.
3. Test results
The test results are shown in table 3.
TABLE 326 indoor bacteriostasis test of kasugamycin and quinazolinone suspending agent on Botrytis cinerea
Note: letters after the same row of numbers indicate significant differences at P < 0.05 level (Duncan's New Bipolar Difference method).
As can be seen from Table 3, the 26% kasugamycin-quinazolinone suspension treated at 500X showed the highest inhibition rate of 90.79% against Botrytis cinerea. The test agent is diluted by 1000 times, and the inhibition rate of the 26% kasugamycin-quinazolinone suspending agent on botrytis cinerea is obviously higher than that of a 2% kasugamycin aqueous solution and a 24% quinazolinone suspending agent. The control effect of the 26% kasugamycin and quinazolinone suspending agent of 2000 x on botrytis cinerea is 71.05%, and the treatment has no significant difference with the treatment of 2% kasugamycin aqueous solution of 1000 x and 24% quinazolinone suspending agent of 1000 x.
Example 8, 26% kasugamycin-quinazolinone suspension on Botrytis cinerea
1. Reagent for testing
2% kasugamycin solution from Qingdao Star brand crop science, Inc
24% quinazolinone suspension, prepared according to the method of example 1
26% kasugamycin quinazolinone suspension, prepared according to example 1
2. Test article and control object:
test work: eggplant of the species Bulita 702
The control object is: gray mold is caused by Botrytis cinerea (Botrytis cinerea)
3. Conditions of the test
The test site is arranged in an eggplant protection site in Shouguang city, Shandong province, and the test for controlling gray mold of eggplant is carried out in a greenhouse in the eggplant protection site in Shouguang city in 2020. The soil is sandy land. The disease is serious. The cultivation conditions and management measures of all the test cells are consistent.
4. Test design and arrangement
In the test, 6 treatments of 26% kasugamycin and quinazolinone suspending agent 500X, 1000X and 2000X, 2% kasugamycin soluble solution, 24% quinazolinone suspending agent 1000 times solution and no-application clear water are designed as controls, and each cell is 24m2The above steps are repeated for 4 times, and all the cells are arranged randomly.
5. Test investigation and calculation method
The disease condition base was investigated before the application of the drug, 7 days after the application of the drug, 15 days after the application of the drug, and 3 times of the whole test investigation. The investigation method adopts a random sampling method to carry out investigation. 5 plants are randomly selected in each cell, 2 branch number brands are selected for each plant, 5 leaves are counted from the branch tip to the lower part after the pro-drug is completely spread, and 50 leaves are investigated in each cell. Statistical analysis of the experimental data was performed using the Duncan new complex pole difference method. During the pesticide application period, the treatment is observed to have no phytotoxicity on the eggplants.
The grading method comprises the following steps:
level 0: no disease spots;
level 1: the lesion area accounts for less than 5% of the whole leaf area;
and 3, level: the lesion area accounts for 6 to 10 percent of the whole leaf area;
and 5, stage: the lesion area accounts for 11 to 20 percent of the whole leaf area;
and 7, stage: the lesion area accounts for 21-50% of the whole leaf area;
and 9, stage: the lesion area accounts for more than 51% of the whole leaf area.
Calculating disease index and prevention and treatment effect according to the following formula:
6. results
6.1 prevention and treatment effects of test agent on Botrytis cinerea
Test results show that the control effects of the 26% kasugamycin-quinazolinone suspending agent diluted by 500 x and 1000 x times are respectively 91.60% and 91.30% 7 days after application, and are obviously higher than those of the other 3 treatments. When the 2% kasugamycin aqueous solution and the 24% quinazolinone suspending agent are diluted by 1000 times and the 26% kasugamycin-quinazolinone suspending agent is diluted by 2000 times, the control effect is equivalent, and no significant difference exists. 15 days after the drug is applied, the treatment control effect of 500 times dilution of 26% kasugamycin and quinazolinone suspending agent is the best, which is up to 91.07%, and the control effect of 1000 times dilution of 26% kasugamycin and quinazolinone suspending agent and 2000 times dilution of the 26% kasugamycin and quinazolinone suspending agent are not obviously different, but are obviously higher than the control effect of 1000 times dilution of 2% kasugamycin aqueous solution and 24% quinazolinone suspending agent.
TABLE 46 field efficacy test of kasugamycin-quinazolinone suspension on Botrytis cinerea
Note: letters after the same row of numbers indicate significant differences at P < 0.05 level (Duncan's New Bipolar Difference method).
Claims (8)
1. A mixed bactericide comprises quinazolinone and kasugamycin as active ingredients;
the mass ratio of the quinazolinone to the kasugamycin is 1-30: 30 to 1.
2. The compounded germicide according to claim 1, wherein: the mass ratio of the quinazolinone to the kasugamycin is 1-12: 12 to 1.
3. The compounded germicide according to claim 1 or 2, characterized in that: the mixed bactericide is a suspending agent, a soluble liquid agent, an aqueous emulsion and water dispersible granules.
4. A compounded biocide as claimed in any one of claims 1 to 3, wherein: in the mixed bactericide, the sum of the mass percentages of the quinazolinone and the kasugamycin is 1-80%.
5. The compounded germicide according to claim 4, wherein: in the mixed bactericide, the sum of the mass percentages of the quinazolinone and the kasugamycin is 1-60%.
6. Use of a compound fungicide according to any one of claims 1-5 for controlling plant diseases.
7. Use according to claim 6, characterized in that: the plant diseases comprise citrus canker, cucumber bacterial angular leaf spot, eggplant wilt, eggplant gray mold and tomato gray mold.
8. Use according to claim 6 or 7, characterized in that: and spraying or canning the mixed bactericide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011453914.5A CN112514902A (en) | 2020-12-09 | 2020-12-09 | Bactericide containing quinazolinone and kasugamycin and application of bactericide in preventing and treating plant diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011453914.5A CN112514902A (en) | 2020-12-09 | 2020-12-09 | Bactericide containing quinazolinone and kasugamycin and application of bactericide in preventing and treating plant diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112514902A true CN112514902A (en) | 2021-03-19 |
Family
ID=74998929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011453914.5A Pending CN112514902A (en) | 2020-12-09 | 2020-12-09 | Bactericide containing quinazolinone and kasugamycin and application of bactericide in preventing and treating plant diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112514902A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113647393A (en) * | 2021-07-27 | 2021-11-16 | 惠州市银农科技股份有限公司 | Suspending agent containing kasugamycin and oxine-copper and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103987261A (en) * | 2011-09-02 | 2014-08-13 | 巴斯夫欧洲公司 | Agricultural mixtures comprising arylquinazolinone compounds |
| CN110537543A (en) * | 2019-06-04 | 2019-12-06 | 广西汇丰生物科技有限公司 | Pesticide composition containing kasugamycin and quinolinone and bactericide |
-
2020
- 2020-12-09 CN CN202011453914.5A patent/CN112514902A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103987261A (en) * | 2011-09-02 | 2014-08-13 | 巴斯夫欧洲公司 | Agricultural mixtures comprising arylquinazolinone compounds |
| CN110537543A (en) * | 2019-06-04 | 2019-12-06 | 广西汇丰生物科技有限公司 | Pesticide composition containing kasugamycin and quinolinone and bactericide |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113647393A (en) * | 2021-07-27 | 2021-11-16 | 惠州市银农科技股份有限公司 | Suspending agent containing kasugamycin and oxine-copper and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109418268B (en) | Bactericidal preparation and application thereof | |
| CN115633697A (en) | Composition containing berberine, medical fertilizer, preparation method and application thereof | |
| CN115885998A (en) | Application of bactericidal composition containing mandipropamid and fluopicolide in preventing and treating phytophthora diseases | |
| CN114208833B (en) | Pesticide composition containing fluroxypyr and diclosulam as well as preparation method and application thereof | |
| CN112514902A (en) | Bactericide containing quinazolinone and kasugamycin and application of bactericide in preventing and treating plant diseases | |
| CN109122687B (en) | Glycolate complex bactericide and application thereof | |
| CN116267928B (en) | Bromide-containing nitroalcohol is a bactericidal composition | |
| CN113767906B (en) | Sterilization composition for preventing and treating muskmelon bacterial angular leaf spot bacteria | |
| CN104996450A (en) | Sterilization composite contained with pyribencarb | |
| CN107873708A (en) | A kind of bactericidal composition and application | |
| CN117770250A (en) | Sterilization composition containing bronopol and application thereof | |
| CN107318865A (en) | The composition pesticide of captan and furametpyr compounding | |
| CN109418280A (en) | A kind of bactericidal composition containing copper 8-hydroxyquinolinate and Mancozeb | |
| CN112616850A (en) | Bactericidal composition containing prothioconazole and allyl isothiocyanate | |
| CN112314610A (en) | Weeding composition containing metamifop, halosulfuron-methyl and butachlor | |
| CN103798262A (en) | Sterilization composition containing thiophanate-methyl and resin acid copper salt | |
| CN116138260B (en) | Sterilization composition containing penoxsulam and benzyl picoxystrobin | |
| CN109006819A (en) | A kind of bactericidal composition and application thereof containing zoxamide Yu biphenyl pyrrole bacterium amine | |
| CN115943963B (en) | Sterilization composition containing methiadin and dichlobentiazox and application thereof | |
| CN119423108B (en) | Application of RNase inhibitor guanosine 5' -monophosphate in improving disease resistance of plants | |
| CN116391719B (en) | Sterilization composition and application thereof | |
| CN117204425B (en) | Cyclobutrifluram-containing sterilization composition and application thereof | |
| CN119014403B (en) | A nano pesticide preparation and its application | |
| CN108064869A (en) | A kind of composition pesticide containing ferimzone and tricyclazole | |
| CN107232233A (en) | It is a kind of to be used to prevent and treat the bactericidal composition of powdery mildew and its applied in powdery mildew is prevented and treated |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210319 |